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Abstract
The aim of this paper is to analyze the sequence of actions in the health system
associated with a particular disease. In order to do that, using Electronic Health
Records, we define a general methodology that allows us to: (i) identify the actions in
the health system associated with a disease; (ii) identify those patients with a complete
treatment for the disease; (iii) and discover common treatment pathways followed by
the patients with a specific diagnosis. The methodology takes into account the
characteristics of the EHRs, such as record heterogeneity and missing information. As
an example, we use the proposed methodology to analyze breast cancer disease. For this
diagnosis, 5 groups of treatments, which fit in with medical practice guidelines and
expert knowledge, were obtained.
Introduction 1
Electronic Health Records (EHRs) are defined as an electronic collection of medical 2
information about the health histories of patients, such as diagnosis, drugs, tests, 3
allergies, and so on [1]. We can observe a simplified example of this type of database in 4
Fig 1. Each row (or record) is made by a medical event that gathers information about 5
the activity performed: patient ID, date, visited hospital service, visited medical 6
specialty, diagnosis and procedure. A suitable manner of representing a medical history 7
of a patient is as a sequence of discrete actions in the health system [2], where the order 8
of events can contain relevant information about the treatment. 9
The aim of this paper is, using EHRs, to analyze the sequence of medical actions in 10
the health system associated with a particular disease. Specifically, for each patient 11
diagnosed with the disease, we would like to extract the sequence of medical actions 12
associated with the complete treatment of it. 13
In order to do that, we design a specific methodology that takes into account the 14
challenging characteristics of the EHRs [3]: 15
• Heterogeneity: The EHR data contains a large amount of distinct medical events 16
(e.g., diagnosis, medication, lab). 17
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Hospital service: Surgery Unit
Hospital specialty: Gynecologic oncology
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Fig 1. A simplified EHR structure.
• Incomplete information: This is a common characteristic in EHRs, where missing 18
values frequently outnumber observed values. In particular, we use a real-world 19
administrative database characterized by the huge number of missing values in the 20
diagnosis variable (75%). 21
This lack of diagnosis values in many medical actions, together with the comorbidity 22
of many patients, creates uncertainty about whether a medical action is associated with 23
a particular disease or not (see Fig 2). In other words, patients are likely to have 24
co-existing diseases, consequently, some actions are unknown which disease treatment 25




Medical action with missing diagnosis
Medical action with the diagnosis of interest
Medical action with other diagnosis
Fig 2. Ambiguity of medical actions associated with a diagnosis due to
comorbidity and missing values.
In light of the above, we propose a general methodology that allows us to: (i) 27
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identify the actions in the health system associated with a disease; (ii) identify those 28
patients with complete treatment of the disease; (iii) and discover common treatment 29
pathways followed by the patients with a specific diagnosis. As an example in a real 30
scenario, we use the methodology to analyze breast cancer disease. The outcomes are 31
compared with clinical practice guidelines to show if the theory and reality match, or, 32
on the contrary, there exist any deviation in practice. 33
Motivation. Previous studies have focused on the identification of clinical pathways 34
and treatment patterns from EHRs using process mining [4–7]. The basic idea of 35
process mining is to extract knowledge from event logs, and in the healthcare domain, 36
medical activities from EHRs are used as process logs [8]. However, most of the health 37
data have diverse behavior and are not well structured. This assumption leads to 38
spaghetti-like workflow models that are very difficult to interpet [7]. 39
Machine learning techniques provide a potential solution to these spaghetti models 40
by grouping patients in relatively homogeneous subgroups. For example, in [9], prior to 41
treatment pathway extraction, the authors used hierarchical clustering with longest 42
common subsequence distance to measure similarity between sequences. In [10] patients 43
were segmented by their outcomes, followed by further clustering using DBScan with 44
Leveinshtein distance, and frequent pattern mining using the SPAM algorithm. In [11] 45
the authors applied fuzzy c-means in order to group the patients according to some 46
selected statistical characteristics. Next, the treatment pathway data were used to 47
generate frequent episodes that characterize each group. Finally, [12] employed K-means 48
together with Leveinshtein distance to obtain subgroups of patients. Subsequently, the 49
typical clinical pathways were represented by directed graphs with the edges weighted 50
according to the flow of each cluster. 51
These models do not deal with common challenges of clinical data such as 52
inaccuracy, incompleteness, comorbidities, active treatments that provide just a partial 53
view of the entire medical history, and so on. Our model is primarily focused on these 54
matters in order to obtain complete treatment pathways for an accurate analysis of the 55
disease. The second reason for developing a new methodology is associated with the 56
identification and representation of the different treatment pathways. There are some 57
approaches that, after grouping the points using a clustering technique, depict the 58
subgroups by the most frequent medical activities instead of the whole set of activities 59
implied [9, 12]. That is, they are represented by a partial set of medical activities rather 60
than by a real and complete treatment pathway. Some other techniques segment the 61
patients by common medical characteristics such as diagnosis or outcomes, and they 62
subsequently construct the typical treatment pathways within each group [10,11]. 63
However, our methodology groups the treatment pathways in subgroups based on their 64
actions and the order in which they occurred. In addition, it enables the representatives 65
of the clusters to be depicted by a real treatment pathway of the disease of interest. 66
Materials and methodology 67
Materials 68
The study is performed on a dataset from the public health care system of the Basque 69
Country (Spain) called Osakidetza. This is a database recording the medical histories of 70
579.798 patients concerning different levels of healthcare (1 hospital, 11 outpatient 71
clinics and emergency care) in 2016 and 2017. Remember that the aim of the study is to 72
analyze the sequence of actions in the health system, therefore, the treatments will be 73
represented as pathways followed in the hospital. For that reason, henceforth, we will 74
only consider hospital services, medical specialties and diagnosis information. Then, we 75
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denote an action as a tuple a = (s,m, d) where s refers to the hospital service visited, 76
m refers to the medical specialty and d refers to the diagnosis. Hence, a treatment 77
pathway of a patient is an ordered sequence of actions A = a1a2...am. 78
These treatment pathways are not associated with a unique disease due to the 79
existence of comorbidity in the patients (see Fig 2). An example is a patient with a 80
diagnosis of diabetes mellitus and lung cancer. When the diagnosis value is missing, we 81
can not assure if the medical action is related to the cancer or to the diabetes condition. 82
Therefore, if we are able to assign each action to a disease, the treatment pathway of a 83
patient can be seen as a set of subsequences of actions associated with different diseases. 84
We refer to the subsequence of actions associated with a diagnosis as disease 85
treatment pathway. 86
Methodology 87
In this section, we present the methodology (Fig 3) to identify the different treatments 88
of a disease followed by the patients in the health system. For this purpose, we 89
developed a methodology to extract complete treatments associated with a diagnosis 90
from the entire medical history of the patients. Afterwards, we applied a clustering 91
method with the aim of identifying the different groups of disease treatment pathways. 92
Note that clustering is an unsupervised technique and it is performed without prior 93
knowledge about the disease. Therefore, although the validation of the clusters could be 94
carried out in terms of compactness or coherence, we thought that the most appropriate 95
evaluation of our approach was by checking the results with medical guidelines and 96












with the diagnosis of
interest
Identification of actions
associated with the 
diagnosis of interest
Identification of patients
with a high probability
of having complete
treatment 
Fig 3. Methodology of the study.
Creation of treatment pathways from EHRs 99
We need to convert the original EHRs (Fig 1) into treatment pathways. As 100
aforementioned, this structure is based on creating a sequence of actions from the 101
records of the database in such a way that each patient has an associated treatment 102
pathway. Therefore, we work on discrete sequences, variable in length because of the 103
great deal of heterogeneity in the medical histories of the patients. For instance, there 104
may exist a patient with only two visits to the hospital just for check ups, whereas 105
another patient suffering from a chronic disease regularly visits the hospital due to 106
therapy, analytics, tests and so on. 107
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Extraction of complete treatments associated with a diagnosis 108
The next goal is the extraction of complete treatment pathways associated with a 109
diagnosis from the EHRs, which is merely the extraction of the subsequence of actions 110
associated with the diagnosis of interest, that is, the disease treatment pathway. Firstly, 111
we identify the patients with the diagnosis of interest recorded. Then, to cope with the 112
lack of diagnosis information and comorbidity in many patients, we determine which 113
actions of the patients are associated with the pathology in order to avoid typical 114
actions of another diagnosis in the disease treatment pathway. Once these pathways are 115
created, we have to select the patients with a high probability of having recorded the 116
complete treatment of the disease, and, eventually, we will be able to obtain the disease 117
treatment pathways of interest from EHRs. 118
Identification of actions associated with a diagnosis. Due to the missing values in the 119
diagnosis together with the comorbidity in patients, we are not able to directly extract 120
the disease treatment pathway. Hence, we propose a relevance measure to identify 121
which are the typical actions related to the diagnosis of interest within a treatment 122
pathway (see Fig 2). In order to do that, we first divide the database into two groups of 123
patients: patients with at least one action with the diagnosis of interest, and patients 124
without it. Then, we check the medical specialty in which the action occurs. We 125
calculate the mean frequency of the medical specialty in both groups, and the relevance 126
is defined as the ratio of the mean frequency between the groups. Now, the higher the 127
relevance is, the more important the action is for the disease. Therefore, we establish a 128
threshold τ in such a way that if the relevance is higher than τ , we include the action in 129




where fmD and fmR are the mean frequency of the times attended to a medical specialty 131
in the patients with the targeted diagnosis and the rest of the patients, respectively. 132
Identification of patients with complete treatments. As previously mentioned, the first 133
step was to identify patients with the diagnosis of interest recorded in the treatment 134
pathways. However, it is not sufficient when it comes to obtaining complete treatments 135
for various reasons: pathways might contain actions of similar diseases (e.g., different 136
types of cancer) that make it difficult to know on which diagnosis the treatment is 137
focused; there might exist treatments which started previously to or finished later than 138
the recording period; or even uncompleted treatments with lost follow-up. Hence, we 139
propose some selection criteria to deal with these issues: 140
• Ensuring that the treatment pathway performed is directly focused on the aimed 141
diagnosis: a requirement to ignore patients with similar coexisting diseases (and 142
therefore, treatments) recorded in their medical histories. 143
• Avoiding treatments started before the recording period of the database or 144
treatments which did not finish before the closing date: medical procedures that 145
are essential to diagnose a disease must be required in every disease treatment 146
pathway. Likewise, having no diagnosis-related actions in the first and last months 147
of the recording period is an important requisite to obtain complete treatments. 148
• Avoiding treatments with incomplete follow-up: a minimum follow-up time and a 149
minimum amount of actions recorded are essential. 150
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These selection criteria must be adjusted specifically to each disease, taking into 151
account that the initial or final actions, as well as the typical timestamps between initial 152
and final actions, are different depending on the diagnosis that was sought after. Once 153
defined, the criteria are applied one by one to the data in order to filter out the patients 154
that do not satisfy the requirements. The main reason for this data reduction is to 155
select the patients that, with a high probability, have the complete treatment of the 156
disease recorded in the data. 157
Summarizing, we achieve the following objectives with the proposed methodology: 158
(i) identifying the actions associated with a diagnosis, and therefore, the disease 159
treatment pathway of the diagnosis of interest by deleting the actions related to other 160
coexisting diseases; (ii) selecting the patients with a high probability of having the full 161
treatment of the diagnosis recorded in the data by applying the selection criteria. In 162
other words, we are able to extract the complete treatments made up by actions 163
associated with the diagnosis of interest. After that, the candidates are ready to be 164
grouped in order to discover the common treatment patterns of the disease. 165
Clustering: K-medoids with edit distance 166
Once the pathways of treatments associated with the diagnosis of interest are selected, 167
that is the sequences that represent complete treatments, we proceed to identify the 168
most significant groups of treatments. Here, the main idea is to group together 169
treatments in such a way that those within a group are similar to each other but are 170
dissimilar to treatments assigned to other groups. Therefore, the clustering method [13] 171
seems to be a logical and promising approach. 172
However, we should previously select a suitable distance measure that enables the 173
comparison of discrete action sequences with variable lengths. For this purpose, the 174
most commonly used sequence distance is the Levenshtein distance [14], which enables 175
us to calculate the similarity (or dissimilarity) between two sequences, and it is defined 176
as follows. 177
Given two strings A1 and A2 over a finite alphabet, the edit distance between A1 178
and A2 can be defined as the minimum weight of transforming A1 into A2 through a 179
sequence of weighted edit operations. These operations are usually defined in terms of 180
insertion, deletion, and substitution of one symbol for another, possibly with different 181
costs for each of these operations. In this work, the cost of insertion and deletion is 1, 182
whereas the cost of substitution is 2. Nevertheless, the edit distance is not sufficient for 183
many applications comparing strings with different lengths. Hence, normalization 184
should be applied to appropriately rate the weight of the edit errors concerning the sizes 185
of the objects that are compared [14,15]. 186
Finally, in order to generate groups of action sequences taking into account their 187
distances, we make use of K-medoids clustering method [16] which is a variance of 188
K-means algorithm but more appropriate for making clusters of sequences of actions for 189
serveral reasons: i) it can be computed using distances between every pair of sequences 190
of actions; ii) it does not require to compute the centroid of a given set of sequences 191
which is computationally intractable and can generate senseless sequences; iii) each 192
cluster of sequences is characterized by a real sequence of actions, called the medoid; 193
and iv) it is more robust to noise and outliers. 194
The medoid sequence of a cluster is defined as the sequence of the cluster that has 195
the lowest average distance to the rest of the sequences belonging to the cluster. In 196
particular, Partitioning Around Medoids [17] is a representative K-medoids clustering 197
algorithm. The basic idea is as follows: it searches for k representative objects in a data 198
set (k medoids) and then assigns each object to the closest medoid in order to create 199
clusters. Its aim is to minimize the sum of dissimilarities between the objects in a 200
cluster and the medoid of the same cluster. 201
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• Step 1. Initial step: arbitrarily choose k of the n data points as the medoids to 202
form initial clusters. 203
• Step 2. Assignment step: associate each data point to the closest medoid. 204
• Step 3. Update step: for each medoid m and each data point x associated to m, 205
swap m and x and compute the average dissimilarity of x to all the data points 206
associated with m. Select the medoid x with the lowest average dissimilarity. 207
Repeat alternating steps 2 and 3 until there is no change in the assignments. 208
Thus, with K-medoids method we avoid creating artificial sequences of actions for 209
characterizing each group because the representative sequences are real sequences 210
belonging to the database. Besides, obtaining these action sequences that minimize the 211
mean distance relative to the rest of the sequences of the group is an NP-hard problem. 212
Results 213
For the validation of the proposed methodology to generate groups of treatments for a 214
given diagnosis, we will use breast cancer patients as a case study using the dataset 215
provided by Osakidetza. 216
Extraction of complete treatments associated with breast cancer 217
First of all, the target population comprised 1456 patients with breast cancer diagnosis 218
out of 579.798 patients between January 1, 2016, and December 31, 2017. This selection 219
of patients from the database is made according to the International Statistical 220
Classification of Diseases and Related Health Problems (10th revision) [18], where every 221
code starting by C50 corresponds to breast cancer diagnosis. 222
Identification of actions associated with breast cancer. Remember that the association 223
of actions with a diagnosis is made through the relevance of the medical specialties 224
(Eq 1). Table 1 shows those medical specialties whose relevance is higher than τ = 3. 225
Only actions carried out in these 18 medical specialties are included when creating the 226
final treatment pathways of patients with breast cancer, but once they are extracted, 21 227
patients out of 1456 had no action which occurred in these medical specialties, therefore, 228
they are excluded from the study. 229
Identification of patients with complete treatments. Once the association between 230
actions and breast cancer diagnosis is known, we can extract for each patient the 231
subsequence of actions that describe the treatment of breast cancer. However, these 232
sequences may be incomplete. Hence, we will select the sequences of actions that have 233
high probability of describing complete treatment pathways of breast cancer. In order 234
to do that, we propose some selection criteria, listed in Fig 4 and explained as follows. 235
First of all, the patients with any other type of cancer diagnosis apart from breast 236
cancer are filtered out, otherwise, we could not distinguish which cancer diagnosis the 237
treatment is focused on. Moreover, to ensure that the pathology has been diagnosed in 238
the recording period of our database, at least one record of a breast biopsy procedure is 239
required. It is the only definitive diagnostic procedure to determine if the suspicious 240
area is cancerous [19], and therefore, should be performed for every breast cancer 241
diagnosed patient. 242
Regarding the recording time of treatments, we consider that a treatment is 243
completely recorded in the database if there is no diagnosis in the first and last months. 244
Therefore, the breast cancer diagnosis must be between the 1st February 2016 and the 245
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Table 1. Relevance of the medical specialties associated with breast cancer
diagnosis.
Medical Specialties Relevance Medical Specialties Relevance
Gynecologic Oncology 85,9 Gynecology 9,3
Radiotherapy 78,3 Genetic Laboratory 8,8
Plastic Surgery 66,0 Surgery Unit 5,8
Medical Oncology 36,4 Anesthesia 5,6
Day Hospital 16,5 Home Hospitalization 4,8
Nuclear Medicine 11,7 Pathological Anatomy 4,2
Day Surgical Hospital 10,5 Hospitalization 3,5
Genetics 10,2 Others 3,3
Major Burns Unit 9,5 Radiology 3,0
Table 1 shows the relevance of the medical speciatlies given at least 3 times more
frequently in breast cancer patients. These are the ones to be considered to create the
breast cancer treatment pathways of patients.
Fig 4. Proposal for the selection criteria of breast cancer diagnosis.
30th September 2017. If any patient with a breast cancer diagnosis record out of this 246
period was included, we assume that it is the continuation of the treatment previously 247
started or the continuation after 2017. 248
For the same reason, we need to avoid radiotherapy or chemotherapy actions in the 249
last period of the database. Radiotherapy is delivered daily or every 2 days, and 250
chemotherapy every 1-3 weeks [19]. Therefore, if there exists any radiotherapy or 251
chemotherapy action in the last 3 weeks of 2017, it means that it is an unfinished 252
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treatment. 253
Likewise, the period of medical assistance recorded must be at least 3 months once 254
the patient has been diagnosed with breast cancer. Additionally, the minimum number 255
of associated actions in their treatment pathways must be at least 15 in order to avoid 256
incomplete sequences of actions, this could mean that patients abandoned the treatment 257
or their follow-up was lost for some reason. 258
After applying these selection criteria, there are in total 440 out of 1456 patients 259
(31.3%) with a high probability to present a complete treatment of breast cancer in our 260
EHRs. These breast cancer treatment pathways are made up of the actions occurred in 261
the aforementioned medical specialties and they are the sequences of actions to be 262
grouped. The treatment pathways are of variable lengths, in fact, the minimum 263
treatment pathway is made of 15 actions and the maximum one of 217 actions. The 264
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Fig 5. Distribution of the length of the breast cancer treatment pathways.
Representative sequences and clinical practice guidelines 266
K-medoids algorithm was applied to the selected disease treatment pathways in order to 267
identify the treatment patterns of breast cancer patients, and the selection of K was 268
checked from 2 to 10. From 5 clusters on, the treatment patterns were repeated, and 269
therefore, we decided to create a total of 5 groups, which are shown in Fig 6. On the 270
one hand, the 5 horizontal lines are the representative disease treatment pathways 271
(medoids), and, on the other hand, the vertical lines correspond to the hospital services 272
visited by the representative patients in each action. 273
To validate the results, the representative pathways were compared with clinical 274
practice guidelines, specifically, with the European Society for Medical Oncology breast 275
cancer guideline [19,20]. These guidelines provide updated state-of-the-art 276
recommendations on management of breast cancer (diagnosis, treatment and follow-up). 277
Besides, the outcomes were also contrasted and approved by physicians. 278
The 5 sequences obtained fundamentally represent different treatment pathways to 279
deal with breast cancer. We can see in Fig 6 that all of them start with Consultation, 280
Pathological Anatomy, Nuclear Medicine and Radiology visits. In these hospital 281
services, the breast examinations and tests are carried out: in Radiology tests such as 282
sonography, mammogram or even some radiography; in the case of Pathological 283
Anatomy and Nuclear Medicine, the biopsy test and cancer diagnosis. According to the 284































Fig 6. Clustering results. Representative medoids considering 5 groups. ANES:
Anesthesia; CONS: Consultation; DHOSP: Day Hospital; EXTC: External Consultation;
FUNT: Functional Testing; HOSP: Hospitalization; NUCM: Nuclear Medicine; NURS:
Nursing; PAU: Post Anesthesia Care Unit; PHAR: Pharmacy; PTAN: Pathological
Anatomy; RADI: Radiology; RTER: Radiotherapy; SURG: Surgery; SWH: Surgery
Without Hospitalization.
clinical practice guideline, a biopsy must be done before any type of treatment is 285
initiated and the five groups accomplish it in Pathological Anatomy actions. 286
The main therapies of each group are as follows (Fig 7): 287
• Group 1 (66 patients, 15 %). 288
– Treatment pattern: Surgery + Chemotherapy + Radiotherapy. 289
– Representative disease treatment pathway: The representative disease 290
treatment pathway is administered by chemotherapy for 15 weeks (the 291
recommended duration is 12-24 weeks) after breast-conserving surgery, and 292
then, a month of radiotherapy is delivered. According to the guideline 293
suggestions, if both therapies are used, chemotherapy should usually precede 294
radiotherapy, as done here. 295
• Group 2 (89 patients, 20.3 %). 296
– Treatment pattern Surgery + Radiotherapy + Hormonal Therapy. 297
– Representative disease treatment pathway: This representative patient 298
combines radiotherapy and hormonal therapy. The medical guideline 299
mentions that hormonal therapy can be delivered safely with radiotherapy 300
and normally lasts 5-10 years. This follow-up cannot be corroborated since 301
the database gathers information over a period of up to 2 years. 302
February 5, 2021 10/17























































Fig 7. Clustering results. Treatment patterns of the groups.
Hitherto, it is worth mentioning that there exist two types of surgery when it 303
comes to breast cancer: breast-conserving surgery, in which the surgical team 304
removes the tumor but tries to keep as much of the breast as possible (it is the 305
preferred local treatment option for the majority of early breast cancer patients, 306
in fact, this procedure is performed in most of the groups); or mastectomy, in 307
which the whole breast is removed. In this latter case it is possible to have no 308
therapy after surgery, and in general terms, these are commonly early invasive 309
breast cancer patients [19]. 310
• Group 3 (108 patients, 24.6%). 311
– Treatment pattern: Surgery + Hospitalization. 312
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– Representative disease treatment pathway: we suspect that it corresponds to 313
the group of patients undergoing mastectomy, since they have no therapy 314
after the surgical procedure, just a sequence of hospitalization actions 315
combined with nursing actions. These hospitalizations after undergoing 316
surgery are probably due to complications, that is, deviations from guidelines 317
since nothing is explicitly mentioned there about hospital stays. 318
– It is one of the groups with the highest number of patients, however, we 319
suspect that some of these patients come from other hospitals just to 320
undergo surgical treatment. We reached this conclusion because, according 321
to practitioners and clinicians, it is not quite common to have such a big 322
number of patients without therapy after surgery. 323
• Group 4 (137 patients, 31.2%). 324
– Treatment pattern: Surgery + Radiotherapy. 325
– Representative disease treatment pathway: The representative patient 326
undergoes breast-conserving surgery, and then receives postoperative 327
radiotherapy, which is highly recommended in practice guidelines. This is the 328
most simple and common delivered treatment. 329
Until now, all the representative treatments start therapy after undergoing 330
surgery, which is called Adjuvant Systemic Treatment. However, the remaining 331
group is the only one that also receives therapy before undergoing surgery. This 332
type of treatment is called Neoadjuvant Systemic Treatment and should be used 333
to reduce the extent of surgery in locally advanced and large operable cancers. 334
• Group 5 (40 patients, 9.1%). 335
– Treatment pattern: Chemotherapy + Surgery + Hospitalization + 336
Radiotherapy. 337
– Representative disease treatment pathway: According to the guidelines, 338
when Neoadjuvant Systemic Treatment is used, all chemotherapy should be 339
delivered preoperatively as done here. In particular, 8 rounds of 340
chemotherapy were delivered in 16 weeks, which comes with the 341
recommendation of 12-24 weeks. Furthermore, they mention that magnetic 342
resonance imaging of the breast, which is a test used to detect breast cancer 343
and other abnormalities, is the most accurate modality for assessing the 344
extent of residual disease following Neoadjuvant Systemic Treatment. It 345
should also be carried out before initializing the treatment for proper 346
comparative evaluation. In this patient they mention it was carried out in 347
the Radiology unit after the 5 first sessions of chemotherapy and once the 348
therapy was finished. After breast-conserving surgery, postoperative 349
radiotherapy was delivered, strongly recommended by the clinical guideline. 350
– We can observe also in this group some hospitalization actions that do not 351
come with medical practice guidelines. 352
The follow-up of the patients is not clearly defined since our database only covers 2 353
years. However, in these 2 years, based on the clinical guideline recommendations, 354
regular visits should be made every 3-4 months. These regular visits correspond to 355
Consultations in the final part of the representative disease treatment pathways. 356
Furthermore, annual bilateral (after breast-conserving treatment) and/or contralateral 357
mammography (after mastectomy) is also recommended. Bilateral mammography in 358
Radiology was performed in the 5 groups. In some cases, they also have Functional 359
Testing actions (groups 1, 2, 3 and 4) or Nuclear Medicine actions (group 1), which are 360
also likely to be related to the follow-up. 361
February 5, 2021 12/17
Discussion 362
The methodology was designed to tackle the missing information and heterogeneity of 363
EHRs. In addition to that, we also faced the difficulty of having comorbidity together 364
with missing diagnosis. Its applicability and effectiveness were tested with breast cancer 365
patients, however, it can be directly applied to identify the different treatment patterns 366
of any other pathology, even for short-duration diseases. Subsequently, a comparison of 367
the outcomes with clinical practice guidelines can be carried out in order to conclude 368
whether they are actually followed in practice or not. It is also worth mentioning that 369
the obtained treatment patterns might be useful for identifying deviations in the 370
treatments from practice guidelines. 371
There exist also some limitations in the application of the proposed methodology. 372
On the one hand, common diagnoses are likely to end up in failure when identifying 373
associated actions, for example, a diagnosis of acute sinusitis. Patients with this type of 374
usual pathologies may visit regular medical specialists (e.g., primary care or 375
consultations), and therefore are unlikely to present high relevance values. That is, they 376
will have no distinctive action in order to extract the associated disease treatment 377
pathways (see Eq 1). In these particular cases, we should ask experts about the most 378
common medical specialties for treating the disease, and afterwards, the clustering 379
would work properly 380
On the other hand, another weakness in the extraction of complete treatments from 381
EHRs appears when the aimed diseases are of long-duration treatment (longer than the 382
recording time of the database). These pathologies will have no complete treatments in 383
the dataset as required in the proposed methodology. In fact, in the particular case of 384
breast cancer, some treatments usually finish with hormonal therapy for 5-10 years, 385
however, the recording time of the dataset is of 2 years. For this reason, we propose a 386
future line of work to resolve this issue, similar to [21]: the design of a method for 387
creating complete treatments of pseudopatients by merging partial treatments. In other 388
words, it consists of aligning the final part of some patients’ disease treatment pathways 389
that coincide, to some extent, with the initial part of others. 390
With regard to the selected clustering method and in comparison with other 391
clustering algorithms, PAM has the drawback of working inefficiently for medium and 392
large data sets. In fact, the complexity of the algorithm is O(n2) just in one iteration. 393
Thus, it is obvious that PAM becomes too costly for large values of n. However, there 394
exist algorithms that improve the performance of PAM, such as CLARA and 395
CLARANS [22]. CLARA repeatedly applies PAM on a subsample of the data set and 396
the remaining objects are assigned to their closest medoid. CLARANS works on the 397
entire data set, but only explores a subset of the possible swaps of medoids and 398
non-medoids using sampling. 399
Furthermore, the time variable is not being exploited in the proposed methodology. 400
Involving this variable in the methodology might improve the results in several 401
ways [23,24]: firstly, in the identification of actions associated with the diagnosis; and 402
secondly, the clustering outcomes would be purer and more homogeneous. We could 403
take advantange of it by including the timestamp in the definition of an action as 404
∆t = ti − ti−1, and then, any action with a ∆t value higher than a threshold τ will not 405
be included in the disease treatment pathways. For instance, in the case of breast 406
cancer, it makes no sense to have a surgical action without any prior breast 407
cancer-related action (e.g., a biopsy procedure) within a period of 2 months. Likewise, 408
the cluster outcomes might be improved if the time were considered when defining the 409
proper distance for comparing sequences: the larger the ∆t value, the larger the 410
penalization between actions, even if the hospital services match. 411
Finally, it would be interesting to include the relevance in the distance between 412
sequences of actions. We computed the relevance as the ratio of mean frequencies of 413
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medical specialties visited in the group of patients with the diagnosis and in the rest of 414
the patients. The ratio, which basically signifies how more frequently each medical 415
specialty is given in the patients with the diagnosis, could be interpreted in terms of 416
importance as something particular of the disease. Then, we could include the obtained 417
relevance values in the edit distance as weights, similar to the Edit Distance with Real 418
penalties [25]. Thus, actions considered proper of the disease would have a higher 419
weight, and consequently, more importance when perfoming the clustering of sequences. 420
Conclusion 421
The EHRs collected from the hospital gathers medical information about 579.798 422
patients, and there therefore exists a great deal of knowledge to be extracted. This 423
information is about the patient ID, date of visit, diagnosis, procedure, hospital service 424
visited and medical specialty visited. 425
Since the objective of the study is to obtain treatment patterns for a given pathology, 426
the first idea is to convert the EHRs into action sequences in such a way that the 427
sequence is able to describe the treatment as a pathway followed in the hospital. Hence, 428
an action is defined as a tuple of diagnosis, hospital services and medical specialty, and 429
consequently, the sequence of actions is the treatment pathway followed by each patient. 430
However, these sequences are characterized by having missing information: 75% of 431
the diagnosis variable are missing values and there exists comorbidity. Consequently, it 432
is difficult to extract the sequence of actions associated with the disease of interest. 433
Even so, once the subsequence is extracted, we do not know whether it is a complete or 434
partial treatment. 435
Therefore, we designed a methodology which is able to cope with all these difficulties 436
and able to obtain the representative treatment patterns from data. Firstly, we need to 437
select only the actions associated with the diagnosis of interest. For this purpose, we 438
defined a relevance measure for an action given in a pathology. Here, we divided the 439
patients into two groups: patients with at least one record with the diagnosis and 440
patients without the diagnosis. Then, we calculated the mean frequency of each medical 441
specialty for both groups. The relevance of an action for a given diagnosis is defined as 442
the ratio between the mean frequency of an action of both groups. Now, a relevance 443
value higher than τ implies that the action is proper of the disease. These actions are 444
selected for creating the disease treatment pathways. Thus, we manage to ignore the 445
actions not related to the diagnosis of interest. Nevertheless, this is not sufficient when 446
it comes to obtaining complete treatments because these disease treatment pathways 447
may be incomplete. Therefore, some selection criteria are defined to extract patients 448
with high probability of having the complete treatment associated with the diagnosis of 449
interest recorded in the data. Finally, to fulfill the objective of identifying the main 450
representative treatment patterns, the patients are grouped by means of the K-medoids 451
algorithm. We chose K-medoids mainly because it groups similar treatments in the 452
same cluster, and because these groups are represented by real treatments. For this 453
purpose, we propose the use of the edit distance, which is able to compare two discrete 454
sequences of different length. 455
The easy applicability of the proposed methodology is worth highlighting as well as 456
its adaptation to different pathologies. In fact, its performance was demonstrated in a 457
real scenario applying the proposed methodology to breast cancer patients. 458
Subsequently, the results were validated with physicians from Osakidetza. 459
The adherence to the European Society for Medical Oncology [19, 20] guidelines was 460
checked with the outcomes obtained, a total of 5 representative sequences. With regard 461
to therapies, the treatment patterns were the following ones: 462
• Surgery + Chemotherapy + Radiotherapy 463
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• Surgery + Radiotherapy + Hormonal Therapy 464
• Surgery + Hospitalization 465
• Surgery + Radiotherapy 466
• Chemotherapy + Surgery + Hospitalization + Radiotherapy 467
In conclusion, the proposed methodology enables us to easily identify the treatment 468
patterns of a pathology from EHRs, despite their missing information concerning the 469
diagnosis. This is a common characteristic of clinical databases, which did not hinder 470
reaching our ultimate objective, as was shown in the breast cancer analysis. 471
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